We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Graffinity Enters into Drug Discovery Research Collaboration with Genentech
News

Graffinity Enters into Drug Discovery Research Collaboration with Genentech

Graffinity Enters into Drug Discovery Research Collaboration with Genentech
News

Graffinity Enters into Drug Discovery Research Collaboration with Genentech

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Graffinity Enters into Drug Discovery Research Collaboration with Genentech"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Graffinity Pharmaceuticals GmbH announced that it has entered into a drug discovery research collaboration with Genentech, Inc, a wholly-owned member of the Roche Group. With this collaboration Genentech will gain access to Graffinity’s proprietary, fragment-based drug discovery technology.

Under the terms of the agreement, Graffinity will receive technology access fees and optional payments for follow-up chemistry for the generation of small molecule hits against a number of drug targets. Financial details of the transaction were not disclosed.

Mathias Woker, Chief Business Officer of Graffinity, stated, ”We are very pleased that Genentech has decided to partner with us in fragment-based drug discovery. This marks our second collaboration with Genentech, and we think that this new agreement demonstrates how attractive Graffinity’s very large fragment library and rapid surface plasmon resonance (SPR) screening technology are.”

Kristina Schmidt, CEO of Graffinity, remarked, ”Our label-free, biophysics-based screening technology has shown to be an important element for companies which choose to work with us. With the help of this technology we enable partners, such as Genentech, to explore drug targets that would remain white spaces on the map of drug discovery, if researchers were limited to other conventional high-throughput screening techniques.”
Advertisement